Circle Pharma, a San Francisco, CA-based early-stage biotech startup, secured an undisclosed amount of seed funding.
Backers included Pfizer and Mission Bay Capital.
Founded by Prof. Matt Jacobson, Ph.D. (U.C. San Francisco) and Prof. Scott Lokey, Ph.D. (U.C. Santa Cruz) and led by President and CEO David J. Earp, J.D., Ph.D., Circle Pharma applies proprietary computational design algorithms and chemistry to develop cell permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diverse macrocycle scaffolds selected for inherent permeability.
The company has also initiated two collaborations with Pfizer to develop cell permeable macrocyclic peptide therapeutics. Its technology is based in part on research sponsored by Pfizer through an agreement with QB3.